.navbar .collapse { display: block; } .mobile-nav { max-height: none !important; } @media screen and (min-width: 1200px) { .navbar #basic-navbar-nav .navbar-nav { position: static !important; } }

Global Perspectives on Advanced Breast Cancer Management

EP. 1: CDK4/6 Inhibitors in HR+ Metastatic Breast Cancer

October 5th 2017

EP. 2: Biomarkers for CDK4/6 Inhibitors in HR+ mBC

October 5th 2017

EP. 3: Efficacy of CDK4/6 Inhibitors in HR+ mBC

October 5th 2017

EP. 4: Differences Among CDK4/6 Inhibitors in HR+ mBC

October 5th 2017

EP. 5: Abemaciclib With Hormone Therapy for HR+ mBC

October 5th 2017

EP. 6: Fulvestrant in the Era of CDK4/6 Inhibitors for HR+ mBC

October 5th 2017

EP. 7: Neoadjuvant PI3 Kinase Inhibitors for HR+ Breast Cancer

October 5th 2017

EP. 8: Post-Adjuvant Therapy for HER2+ Breast Cancer

October 5th 2017

EP. 9: Adjuvant Therapy for ER+/HER2+ Breast Cancer

October 5th 2017

EP. 10: Breast Cancer: Dual HER2-Targeted Adjuvant Therapy

October 5th 2017

EP. 11: HER2+ Breast Cancer: Neratinib Patient Selection

October 5th 2017

EP. 12: PARP Inhibitors for BRCA-Associated TNBC

October 5th 2017

EP. 13: Role of Neoadjuvant Platinum-Based Therapy for TNBC

October 5th 2017

EP. 14: AR-Targeted Therapy and Immunotherapy for TNBC

October 5th 2017

EP. 15: The Path Forward in Breast Cancer Research

October 5th 2017